Achillion Pharma (ACHN) Misses Q1 EPS by 1c; Joseph Truitt Appointed Chief Executive Officer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Achillion Pharma (ACHN) Misses Q1 EPS by 1c; Joseph Truitt Appointed Chief Executive Officer

Achillion Reports First Quarter 2018 Financial Results and Management Transition

May 2, 2018 6:35 AM EDT

 - Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 -

 - Joseph Truitt appointed Chief Executive Officer -

NEW HAVEN, Conn., May 02, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway, today reported financial results for the three months ended March 31, 2018. For the first quarter of 2018, the Company reported a net loss... More